Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Efficacy and Safety of Lenvatinib Plus Bevacizumab and a PD-1 Inhibitor Versus Bevacizumab Plus a PD-1 Inhibitor After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study

NCT07870772 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07870772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07870772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Efficacy and Safety of Lenvatinib Plus Bevacizumab and a PD-1 Inhibitor Versus Bevacizumab Plus a PD-1 Inhibitor After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
July 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellulcar carcinoma